Basic Information
Angiosyn Inc. develops novel proprietary biologics to control angiogenesis. The company’s initial therapeutic indications are ophthalmic diseases, such as macular degeneration and diabetic retinopathy, where angiogenesis can lead to vision loss and blindness.
Angiosyn Inc.
California,United States of America
unclear
January 01, 2003
--
info@angiosyn.com
Enterprise Profile
Industrial Sector
Concept
Application Scenarios